Abbott’s Allen Burton, MD, discusses the Company’s new recharge-free Proclaim XR Neurostimulation System in an interview with SmartTRAK

In the market for Spinal Cord Stimulation (SCS), companies have been looking at different ways to extend the battery life of an implantable pulse generator (IPG) and minimize the amount of time patients spend recharging a device. One competitor that’s making advances in battery longevity is Abbott Laboratories.

Armed with its own research that showed patients do not like recharging, Abbott launched the recharge-free Proclaim Elite SCS in 2017 with a patient-centric strategy and an eye for capturing share in the US SCS market. Since then, there have been questions about battery life, and whether or not a recharge-free IPG would have to be replaced more frequently than a rechargeable SCS.

We are pleased to announce that Stacy Spirito has joined the team at SmartTRAK as Director of Sales. Stacy has spent 14+ years in the medical device and technology industries, most recently as an Account Executive with Gartner, working with Investors.  Prior to that, Stacy was part of a sales team that launched a disruptive new medical device for breast cancer at Mammotome/Leica Biosystems. 

Meet Stacy Spirito:

1. Stacy, what is your role with SmartTRAK? My role at SmartTRAK is Director of Sales. I will be developing and managing the relationship with our clients and ensuring we are providing value and actionable insights to enable them to deliver on their key initiatives.
   
   

SmartTRAK is pleased to welcome Anikó Szekér, the newest addition to our Wound Care team. Anikó has 10+ years of medical device experience in Wound Care and Surgical single use products. Before joining SmartTRAK, Anikó was  Marketing Manager, Eastern Europe Wound Care and Surgical at Mölnlycke Health Care.

Location: Northeast region of US (NY, NJ, MA, PA)

Full-time Position

Position:

BioMedGPS, a leading strategic advisory and healthcare analytics firm serving the life sciences industry, is seeking a Director of Enterprise Sales with extensive healthcare B2B experience for its SmartTRAK Business Intelligence platform and related products. Applicant must reside in the Northeastern region of the USA for easy access to major accounts.

SmartTRAK is the first business intelligence portal that provides real time data, analytics and curated content by a team of industry experts to help medical device executives make more informed strategic decisions. SmartTRAK is utilized by leading medical device companies within the orthopedic, wound care, regenerative medicine and neuro therapeutic areas. The Director of Sales will be responsible for selling SmartTRAK’s suite of business intelligence solutions to C- suite and other senior level executives, as well as building long term strategic programs and relationships at all levels of the enterprise.

It was a busy year, and SmartTRAK, the leading provider of real-time market data, analysis and advisory services for the orthopedic, wound, regenerative medicine and neuro therapies markets, covered all the key industry happenings in 2019, providing comprehensive industry coverage of the latest trends, news, intel and interviews most important to you.

And if you'd like to stay on top of hot trends and technologies in 2020 in the ortho, wound, regen and neuro markets, make sure to sign up to receive a weekly summary of our latest blog posts.

Here are SmartTRAK's Top 10 blog posts of the past year with two bonus posts, because at SmartTRAK we always strive to deliver more than what's expected!

The US market for Hemostats and Sealants grew +5.6% YoY in Q319, a continued deceleration from +6.4% YoY in Q219, with fibrin sealants and absorbable hemostats driving the increase.

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market experienced revenue growth in Q319. Leading the way was Becton Dickinson (BD), with Integra, Ethicon and Baxter all posting strong gains. The US Hemostats and Sealants market was up +5.6% YoY with all competitors posting gains for the quarter. Sealants continued their solid growth, up +6.5% YoY, with fibrin sealants leading the way. Absorbable hemostats resumed their leadership, contributing to the +5.1% YoY growth to...

Among the many topics covered in the complete, comprehensiveQ319 US Hemostats and Sealants Market Recap* are:

The SCS market is still down YoY, but improved sequentially as companies get back on track

In Q319, US and WW spinal cord stimulation (SCS) revenues continued to be down YoY against tough comps, but the rate of decline slowed sequentially for most companies as they address ongoing commercial execution issues, customer destocking and initiate new product launches. In the US, SCS revenue was down -4.7% in Q318 according to SmartTRAK Financial Dashboard, an improved sequential growth rate vs a -6.3% YoY decline in Q219. On a WW basis, the SCS market followed a similar pattern, with Q319 revenue of...

Among the many topics covered in the complete, comprehensive Q319 SCS Market Recap* are:

The orthopedic robotics market continues to gain momentum and validation with increasing competition and development milestones being met by key companies in the space.

Positive gains in the mid-single digits for Q319, a slight decrease from previous quarter

Prevention of HAIs continues to drive measures and practices to reduce Central Line Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. In response, numerous programs and educational tools are being launched providing measures and strategies to assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Last quarter, a coalition of nurses and the AVA launched a drive to support a safety initiative for placing vascular access specialists in every hospital across America. This theme continued at this year’s AVA conference with the mission statement of “Protect the Patient, Educate the Clinician and Save the Line” highlighting the overall focus for the event. Acknowledgment of the importance of the vascular access nurse and team were featured in numerous studies and presentations demonstrating the value of the vascular access team in practice...

Among the many topics covered in the complete, comprehensive Q319 US Infection Prevention Market Recap* are:

Easy YoY comps along with new product introductions help drive sequential growth 

SmartTRAK reports that In Q319, the WW Trauma Market (defined as fixation of the pelvis, femur & proximal/shaft portion of the tibia) increased +3.7% (as reported), with the US posting +4.6% growth. Q319 WW share leaders remained relatively steady compared to last year, with top trauma player DePuy Synthes, followed by Stryker, Zimmer Biomet and Smith & Nephew. The WW Trauma Market Segment shares were...

Among the many topics covered in the complete, comprehensive  Q319 Trauma Market Recap*  are: